FDA ONP Leadership On Switches Could Benefit Chronic Therapies
This article was originally published in The Pink Sheet Daily
FDA’s new Office of Nonprescription Products takes the lead on Rx-to-OTC switches from therapeutic divisions. ONP Deputy Director Rosebraugh says the agency’s thinking on chronic therapies as switch candidates has evolved, cites smoking cessation.
You may also be interested in...
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.
A committee comprising stakeholders will discuss ways of improving USP's work with international pharmacopeias to harmonize excipient monographs and general chapters.